The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK

The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK

Pokaż inne wersje (2)

Opis bibliograficzny
Główni autorzy:	Robson, J, Kiran, A, Maskell, J, Hutchings, A, Arden, N, Dasgupta, B, Hamilton, W, Culliford, D, Emin, A, Luqmani, R
Format:	Journal article
Wydane:	2013

Podobne zapisy

The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.
od: Robson, J, i wsp.
Wydane: (2015)

The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK
od: Robson, J, i wsp.
Wydane: (2015)

PREDICTORS OF AORTIC ANEURYSMS FOR GIANT CELL ARTERITIS SUBJECTS
od: Robson, J, i wsp.
Wydane: (2013)

Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study
od: Robson, J, i wsp.
Wydane: (2016)

THU0297 A novel ultrasound scoring system for giant cell arteritis
od: Monti, S, i wsp.
Wydane: (2017)

THU0302 Histology findings in giant cell arteritis (GCA) and their relationship with the ultrasound results: analysis of data from the tabul study (temporal artery biopsy vs ultrasound in diagnosis of giant cell arteritis)
od: Ponte, C, i wsp.
Wydane: (2017)

P1_41 Histology findings in giant cell arteritis (GCA) and their relationship with the ultrasound results: analysis of data from the TABUL study (Temporal Artery Biopsy vs Ultrasound in diagnosis of Giant Cell Arteritis)
od: Ponte, C, i wsp.
Wydane: (2017)

Giant femoral aneurysm in giant cell arteritis
od: Muhammed Bayram, i wsp.
Wydane: (2022-01-01)

Aortic dissection and accelerated aneurysmal degeneration in a patient with giant cell arteritis
od: Maged Metias, MSc, MD, i wsp.
Wydane: (2020-12-01)

Giant carotid aneurysm in takayasu arteritis
od: Debasis Acharya, i wsp.
Wydane: (2022-01-01)

The lifetime risk of total hip and knee arthroplasty: results from the UK general practice research database.
od: Culliford, D, i wsp.
Wydane: (2012)

The lifetime risk of total hip and knee arthroplasty: results from the UK general practice research database.
od: Culliford, D, i wsp.
Wydane: (2012)

The frequency and severity of patient-reported symptoms in giant cell arteritis
od: Monti, S, i wsp.
Wydane: (2017)

THE FREQUENCY AND SEVERITY OF PATIENT-REPORTED SYMPTOMS IN GIANT CELL ARTERITIS
od: Monti, S, i wsp.
Wydane: (2017)

Vascular Endothelial Growth Factor as an Aid to Diagnosis of Giant Cell Arteritis
od: Goodfellow, N, i wsp.
Wydane: (2016)

Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
od: Goodfellow, N, i wsp.
Wydane: (2017)

A population-based survival analysis describing the association of body mass index on time to revision for total hip and knee replacements: results from the UK general practice research database
od: Culliford, D, i wsp.
Wydane: (2013)

The association of vascular risk factors with visual loss in giant cell arteritis
od: Yates, M, i wsp.
Wydane: (2016)

FRI0312 The frequency and severity of patient-reported symptoms in giant cell arteritis
od: Monti, S, i wsp.
Wydane: (2017)

FRI0028 Vascular Endothelial Growth Factor as An Aid To Diagnosis of Giant Cell Arteritis
od: Goodfellow, N, i wsp.
Wydane: (2016)

Clinical Images: Pulmonary Arteritis in Clinically Occult Aneurysmal Giant Cell Arteritis
od: Victoria L Johnson, i wsp.
Wydane: (2021-05-01)

Giant cell arteritis: Current treatment and management
od: Ponte, C, i wsp.
Wydane: (2015)

O08 Blindness in patients with giant cell arteritis and its association with vascular disease
od: Yates, M, i wsp.
Wydane: (2016)

Temporal changes in the rates of total and unicondylar knee replacements in the UK
od: Maskell, J, i wsp.
Wydane: (2008)

2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis
od: Ponte, C, i wsp.
Wydane: (2022)

European Headache Federation recommendations for neurologists managing giant cell arteritis
od: S. P. Mollan, i wsp.
Wydane: (2020-03-01)

Giant cell arteritis: a review
od: Patil P, i wsp.
Wydane: (2013-03-01)

NSAID USE BEFORE AND AFTER 28068 HIP AND 23634 KNEE ARTHROPLASTIES: RESULTS FROM THE UK GENERAL PRACTICE RESEARCH DATABASE
od: Maskell, J, i wsp.
Wydane: (2009)

2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis
od: Ponte, C, i wsp.
Wydane: (2022)

Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward?
od: Luqmani, R
Wydane: (2007)

Microbiomes of Inflammatory Thoracic Aortic Aneurysms Due to Giant Cell Arteritis and Clinically Isolated Aortitis Differ From Those of Non-Inflammatory Aneurysms
od: Ted M. Getz, i wsp.
Wydane: (2019-03-01)

Future Projections Of Total Hip And Knee Arthroplasty In The Uk: Results From The Uk Clinical Practice Research Datalink.
od: Culliford, D, i wsp.
Wydane: (2015)

The effect of hip and knee arthroplasty on oral anti-inflammatory use and the relationship to body mass index: results from the UK general practice research database.
od: Bolland, B, i wsp.
Wydane: (2011)

Association between vascular FDG uptake during follow-up and the development of thoracic aortic aneurysms in giant cell arteritis
od: Daniel Blockmans, i wsp.
Wydane: (2024-03-01)

Giant cell arteritis: new concepts, treatments and the unmet need that remains
od: Coath, F, i wsp.
Wydane: (2018)

ARE WE MEETING THE STANDARDS FOR TEMPORAL ARTERY BIOPSY IN GIANT CELL ARTERITIS?
od: Soni, A, i wsp.
Wydane: (2009)

Giant abdominal aortic aneurysms
od: Joshua I. Ng, BSE, i wsp.
Wydane: (2021-12-01)

Giant Aortic Thoracoabdominal Aneurysm
od: Filipe Machado, i wsp.
Wydane: (2020-01-01)

Giant Cell Arteritis
od: E. V. Shevchenko, i wsp.
Wydane: (2025-01-01)

Tumor necrosis factor-blocking agents in polymyalgia rheumatica and giant cell arteritis - Reply
od: Luqmani, R
Wydane: (2008)